Saturday, 31 October 2026European Markets

AFFLUENT MEDICAL Stock Was 15.22% Up Before The Weekend

Loading stream...

(vianews) - the market ended the session with affluent medical (afme.pa) jumping 15.22% to €2.12 on friday, after five successive sessions in a row of gains. cac 40 slid 0.03% to €7,568.82, following the last session's downward trend on what was a somewhat negative trend trading session today.

affluent medical's last close was €1.84, 43.82% under its 52-week high of €3.28.

about affluent medical

affluent medical sa develops minimally invasive medical devices for the treatment of heart and vascular diseases in france. it develops kardiozis technology for the treatment of abdominal aortic aneurysm; kalios and epygon implants to treat mitral insufficiency; and artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. the company was founded in 2011 and is based in aix-en-provence, france.

earnings per share

as for profitability, affluent medical has a trailing twelve months eps of €-0.65.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -39.36%.

yearly top and bottom value

affluent medical's stock is valued at €2.12 at 21:30 est, way under its 52-week high of €3.28 and way higher than its 52-week low of €1.10.

revenue growth

year-on-year quarterly revenue growth declined by 25.8%, now sitting on 1.34m for the twelve trailing months.

volatility

affluent medical's last week, last month's, and last quarter's current intraday variation average was 9.53%, 2.43%, and 2.60%.

affluent medical's highest amplitude of average volatility was 9.53% (last week), 3.32% (last month), and 2.60% (last quarter).

moving average

affluent medical's value is way higher than its 50-day moving average of €1.23 and way higher than its 200-day moving average of €1.48.

more news about affluent medical (afme.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com